CEL-SCI (CVM) Competitors $2.44 +0.15 (+6.55%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.00 (+0.20%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. COEP, SXTC, SCYX, NRSN, TPST, CARA, TENX, LSTA, CYTH, and FBLGShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Coeptis Therapeutics China SXT Pharmaceuticals SCYNEXIS NeuroSense Therapeutics Tempest Therapeutics Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Cyclo Therapeutics FibroBiologics Coeptis Therapeutics (NASDAQ:COEP) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation. Which has more volatility & risk, COEP or CVM? Coeptis Therapeutics has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Which has higher earnings & valuation, COEP or CVM? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-1.43CEL-SCIN/AN/A-$26.92M-$12.61-0.19 Is COEP or CVM more profitable? CEL-SCI's return on equity of -238.05% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -282.39% -127.23% CEL-SCI N/A -238.05%-104.65% Does the media favor COEP or CVM? In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 1 articles in the media. Coeptis Therapeutics' average media sentiment score of 0.00 equaled CEL-SCI'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CEL-SCI 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of COEP or CVM? 13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 9.9% of CEL-SCI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCoeptis Therapeutics beats CEL-SCI on 5 of the 8 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$7.40M$207.74M$5.47B$20.52BDividend YieldN/AN/A5.25%3.76%P/E Ratio-5.08N/A27.0027.79Price / SalesN/A259.79435.7540.48Price / CashN/A22.4436.8222.26Price / Book16.275.707.984.58Net Income-$26.92M-$96.61M$3.16B$982.91M7 Day Performance2.95%1.15%3.69%1.31%1 Month Performance2.52%0.30%2.91%4.85%1 Year Performance-93.28%10.37%34.30%14.09% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.0822 of 5 stars$2.44+6.6%N/A-93.7%$7.40MN/A-5.0843News CoverageCOEPCoeptis Therapeutics0.194 of 5 stars$7.80+0.3%N/A+37.5%$27.34MN/A-1.342News CoverageSXTCChina SXT Pharmaceuticals0.1482 of 5 stars$1.73+0.6%N/A-79.7%$27.22M$1.93M0.0090News CoverageSCYXSCYNEXIS0.258 of 5 stars$0.67-2.4%N/A-62.1%$26.98M$3.75M-1.2060NRSNNeuroSense Therapeutics1.6923 of 5 stars$1.89-0.5%$14.00+640.7%+69.9%$25.97MN/A-3.5010TPSTTempest Therapeutics1.5558 of 5 stars$6.80-1.4%$30.00+341.2%-73.0%$25.41MN/A-0.3820CARACara Therapeutics0.3383 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.2676 of 5 stars$5.76-1.5%$17.50+203.8%+81.4%$24.27MN/A-2.329LSTALisata Therapeutics2.48 of 5 stars$2.90+3.6%$15.00+417.2%-29.3%$24.12M$1M-1.2630Gap DownCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FBLGFibroBiologics2.8931 of 5 stars$0.62+0.7%$13.00+1,989.4%-87.7%$23.65MN/A-2.9610News Coverage Related Companies and Tools Related Companies Coeptis Therapeutics Competitors China SXT Pharmaceuticals Competitors SCYNEXIS Competitors NeuroSense Therapeutics Competitors Tempest Therapeutics Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Lisata Therapeutics Competitors Cyclo Therapeutics Competitors FibroBiologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
